Quantum-Si/$QSI
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Quantum-Si
Quantum-Si Inc is a life sciences company focused on proteomics research and analytical technologies. It develops single-molecule detection platforms designed to enable next-generation protein sequencing (NGPS) and large-scale protein analysis. Its technology supports massively parallel sequencing of proteins and can also be applied to the study of nucleic acids, providing tools for researchers and clinical applications in molecular analysis. The company's revenue is derived from sales of products and services.
- Ticker
- $QSI
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 145
- Headquarters
- Branford, United States
- Website
- www.quantum-si.com
Quantum-Si Metrics
BasicAdvanced
$317M
-
-$0.46
3.25
-
Price and volume
Market cap
$317M
Beta
3.25
52-week high
$2.19
52-week low
$0.69
Average daily volume
10M
Financial strength
Current ratio
9.969
Quick ratio
9.359
Long term debt to equity
0.008
Total debt to equity
0.018
Profitability
EBITDA (TTM)
-87.36
Gross margin (TTM)
35.02%
Net profit margin (TTM)
-6,138.26%
Operating margin (TTM)
-5,742.06%
Effective tax rate (TTM)
0.10%
Revenue per employee (TTM)
$10,000
Management effectiveness
Return on assets (TTM)
-25.72%
Return on equity (TTM)
-49.11%
Valuation
Price to revenue (TTM)
195.448
Price to book
1.76
Price to tangible book (TTM)
1.76
Price to free cash flow (TTM)
-3.348
Free cash flow yield (TTM)
-29.87%
Free cash flow per share (TTM)
-0.436
Growth
Revenue change (TTM)
-52.96%
Earnings per share change (TTM)
-29.47%
3-year revenue growth (CAGR)
51.78%
3-year earnings per share growth (CAGR)
-17.37%
What the Analysts think about Quantum-Si
Analyst ratings (Buy, Hold, Sell) for Quantum-Si stock.
Analyst projections of the future price of Quantum-Si stock.
Bulls say / Bears say
Interim tests on Proteus showed markedly stronger sequencing than Platinum Pro: the company reported 30 times more alignments in a single-chamber control test and 1.6 to 2.0 times more peptides in protein mixtures. If those developmental results hold in a commercial system, they could give QSI a meaningful performance advantage. (Quantum-Si)
QSI has demonstrated detection of 19 amino acids in its Proteus development programme and is working to put that capability into a sequencing kit. Reaching all 20 would address a key technical milestone for the platform. (Quantum-Si)
A peer-reviewed study of QSI’s Platinum platform cut sample preparation from 32 hours to 10 and showed sequencing in crude bacterial lysate, with a full workflow under 24 hours. This provides evidence that the technology may have practical research uses beyond a laboratory demonstration. (ACS Omega)
QSI pushed Proteus’ expected launch to the second quarter of 2027 from late 2026, adding another instrument design cycle for manufacturing readiness and system repeatability. The delay postpones the product central to its growth plans and highlights execution risk. (Quantum-Si)
Commercial sales remain very small and are falling: second-quarter revenue was $344,000, down from $591,000 a year earlier, and QSI expects about $1 million of revenue for 2026. That leaves little current sales evidence that customers are adopting the platform at scale. (Quantum-Si)
The company remains deeply loss-making, with a $45.2 million net loss and $44.1 million of operating cash used in the first half of 2026. Sustained high spending means QSI’s long-term investment case depends on turning development into meaningful revenue before its cash reserve is depleted. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 29 Oct 2026.
Quantum-Si Financial Performance
Revenues and expenses
Quantum-Si Earnings Performance
Company profitability
Upcoming events
No upcoming events
Quantum-Si News
AllArticlesVideos
Funds containing Quantum-Si
Fund name | Fund size | $QSI weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.02% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.